Diplomat Pharmacy Inc (NYSE:DPLO) had its target price lifted by Cowen and Company from $12.00 to $17.00 in a report released on Tuesday. Cowen and Company currently has a market perform rating on the stock.
Other research analysts have also issued research reports about the company. Zacks Investment Research raised Diplomat Pharmacy from a sell rating to a hold rating in a research note on Monday, February 6th. Mizuho reissued a neutral rating and set a $17.00 price target on shares of Diplomat Pharmacy in a research note on Wednesday, March 1st. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of $23.14.
Diplomat Pharmacy (NYSE:DPLO) opened at 18.08 on Tuesday. The stock has a market cap of $1.21 billion, a P/E ratio of 72.03 and a beta of 0.69. The company’s 50-day moving average price is $15.38 and its 200-day moving average price is $15.04. Diplomat Pharmacy has a 12 month low of $12.25 and a 12 month high of $38.94.
Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings results on Monday, May 8th. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.04. Diplomat Pharmacy had a return on equity of 10.47% and a net margin of 0.77%. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the prior year, the company posted $0.23 EPS. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. Equities analysts forecast that Diplomat Pharmacy will post $0.65 earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of DPLO. Advisor Group Inc. raised its position in shares of Diplomat Pharmacy by 21.1% in the third quarter. Advisor Group Inc. now owns 3,614 shares of the company’s stock valued at $102,000 after buying an additional 629 shares during the period. JPMorgan Chase & Co. raised its position in shares of Diplomat Pharmacy by 73.1% in the first quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after buying an additional 3,056 shares during the period. Sei Investments Co. purchased a new position in shares of Diplomat Pharmacy during the third quarter valued at $139,000. BNP Paribas Arbitrage SA raised its position in shares of Diplomat Pharmacy by 13.8% in the first quarter. BNP Paribas Arbitrage SA now owns 8,876 shares of the company’s stock valued at $142,000 after buying an additional 1,073 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Diplomat Pharmacy during the first quarter valued at $160,000. 74.33% of the stock is currently owned by institutional investors.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.